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Fragments and hot spots in drug discovery
Sandor Vajda, Adrian Whitty and Dima Kozakov 
Drug discovery requires finding a “plug” that fits 
extremely well and with high specificity into a functional 
site on a protein target. This difficult task often requires 
screening of very large compound libraries, and on 
occasion screening finds no useful compounds at all. For 
many years, a failed screening effort left unanswered 
whether this outcome resulted from the absence of suitable 
compounds in the particular screening library used, or 
instead indicated that the target contained no “druggable” 
site, and was therefore intractable for small molecule 
drug discovery. This dilemma was partly resolved by the 
advent of fragment-based drug discovery (FBDD) [1], 
a method that exploits the fact that it is easier to find a 
very small, simple compound that complements just 
a small region within a binding site than it is to find a 
larger, more complex molecule that matches the entire site 
[2]. In FBDD the target of interest is screened against a 
library of low molecular weight (typically 150-250 Da) 
compounds called “fragments”. Compared to conventional 
high throughput screening, fragment screens give much 
higher hit rates, and typically require testing of only 1000-
2000 compounds to establish the druggability of the target 
and to identify initial hits [1]. 
Due to their small size, fragments bind with very 
low affinity, a KD of 1 mM being typical, and so require 
extensive elaboration to achieve the high affinity and other 
properties required for a useful lead compound. Selecting 
which fragment hits provide the best starting points for 
drug discovery is thus a critical decision. The concept 
of Ligand Efficiency [3] has provided an important 
quantitative tool for assessing fragment hit quality. 
However, until recently it has been unclear how to tell 
which fragment hits additionally have a binding mode that 
is sufficiently robust to serve as a basis for growing into 
a larger, higher affinity ligand. Moreover, although it has 
been recognized for some time that the hit rate for a given 
target in a fragment screen gives a good indication of the 
potential to ultimately obtain a high affinity, druglike 
ligand, the theoretical basis for this observation has been 
unclear.
Recent work has shown that considering a 
binding site in terms of the number, strength and spatial 
arrangement of binding energy “hot spots” provides 
answers to these questions. Different regions of a protein 
surface have different abilities to interact with ligands, 
depending on local concavity and physicochemical 
composition. Regions that can contribute large amounts 
of binding energy are called hot spots [4], and can be 
identified experimentally through alanine scanning 
mutagenesis or by their tendency to bind organic solvents 
or fragments, or by computational methods. Our own 
contributions have used the computational method FTMap 
[5], in which small organic probes are positioned on a 
dense grid around the surface of the protein, and those 
probes that interact favorably are identified, subjected 
to energy minimization, and clustered. This process is 
repeated using multiple probe types, the results from 
which are superimposed. Sites that bind a large number 
of probe clusters coincide with binding energy hot spots. 
The energetic importance of hot spots on a given protein 
is determined by the number of probe clusters that overlap 
at each site.
In recent years we have established that the hot 
spots identified by FTMap agree with those identified 
by experimental fragment screening, with the results 
of alanine scanning mutagenesis studies, and with the 
binding site locations of known inhibitors. Recently 
we have shown that hot spot analysis can be used to 
evaluate whether a protein is druggable by small molecule 
inhibitors [6]. As might be expected, a protein without 
a strong hot spot cannot bind any ligand with high 
affinity. We have also shown that the top-ranked hot spot 
dominates ligand binding, such that only fragments that 
achieve good spatial overlap at this main hot spot are very 
likely to maintain their binding mode as the fragment is 
extended to form a larger, stronger-binding ligand [7]. A 
consequence is that a target with a main hot spot that is too 
large and diffuse to be encompassed by a fragment-sized 
ligand may be a poor choice for FBDD, even though it is 
potentially druggable using other methods. The locations 
of other nearby hot spots provide important guidance as to 
which directions to grow the fragment to increase affinity. 
Overall, this recent work shows that the strengths 
and arrangement of hot spots can be used to establish 
whether a target is druggable, whether FBDD is an 
appropriate approach for lead identification, to evaluate 
fragment hits to identify those with the best potential 
for advancement, and to suggest in which directions 
fragments should be extended for increased affinity. For 
targets that are not druggable using conventional druglike 
compounds, hot spot analysis using FTMap provides 
insight into whether they might be addressed using larger, 
non-canonical drug chemotypes such as macrocycles [6]. 
Importantly, this information is obtained using the X-ray 
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crystal structure of the unbound protein, so is useful for 
novel or highly challenging targets for which no ligands 
are known. The hot spots of any protein can be easily 
determined using the free FTMap server (http://ftmap.
bu.edu/) [5].
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